All In Biotech

Drug Trial Radar · NCT03625102

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Feb 12, 2018

Primary completion

Jun 16, 2023

Study completion Jun 16, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.

Conditions

  • HBV

Interventions

  • AntroquinonolDrug

    Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.

  • placeboOther

    The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. quantitative hepatitis B surface antigen (Log qHBsAg)Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chung Shan Medical University Hospital

    Taichung, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.